Global Expansion Hikma Pharmaceuticals has significantly expanded its international footprint through a public listing since 2005 and recent investments of over $1 billion into manufacturing and R&D facilities in Ohio and New Jersey, presenting opportunities to supply advanced manufacturing equipment, raw materials, or quality assurance services.

Manufacturing Growth With 29 manufacturing plants and a commitment to increasing production capacity to support over 12 billion doses annually, Hikma requires ongoing supply chain solutions, process automation, and equipment upgrades to sustain and accelerate growth in high-demand markets.

Research and Innovation Operating across nine R&D centers, Hikma invests heavily in innovation, offering sales prospects for pharmaceutical research tools, advanced laboratory equipment, and novel drug development technologies to support its pipeline expansion.

Market Diversification Serving North America, MENA, and Europe, Hikma's diverse geographic presence provides opportunities to tailor product offerings, compliance services, and regional supply chain solutions to meet varying regulatory standards and market needs.

Strategic Leadership Changes Recent leadership changes, including a new CFO joining the board, signal strategic refinements and potential focus on operational efficiency, offering opportunities to engage with consultancy, financial planning, and corporate services to support Hikma’s evolving corporate objectives.